PDS Biotechnology Corporation
PDSB
$0.79
$0.022.27%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 13.08M | 12.89M | 13.64M | 13.76M | 13.87M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.23M | 34.27M | 35.33M | 36.32M | 39.37M |
| Operating Income | -32.23M | -34.27M | -35.33M | -36.32M | -39.37M |
| Income Before Tax | -36.05M | -37.77M | -37.54M | -38.48M | -41.43M |
| Income Tax Expenses | -1.17M | -1.17M | -2.04M | -869.20K | -869.20K |
| Earnings from Continuing Operations | -34.89 | -36.60 | -35.50 | -37.61 | -40.56 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.89M | -36.60M | -35.50M | -37.61M | -40.56M |
| EBIT | -32.23M | -34.27M | -35.33M | -36.32M | -39.37M |
| EBITDA | -32.17M | -34.21M | -35.27M | -36.26M | -39.31M |
| EPS Basic | -0.82 | -0.92 | -0.94 | -1.04 | -1.17 |
| Normalized Basic EPS | -0.53 | -0.59 | -0.62 | -0.66 | -0.74 |
| EPS Diluted | -0.82 | -0.92 | -0.94 | -1.04 | -1.17 |
| Normalized Diluted EPS | -0.53 | -0.59 | -0.62 | -0.66 | -0.74 |
| Average Basic Shares Outstanding | 170.78M | 160.72M | 151.51M | 145.80M | 139.98M |
| Average Diluted Shares Outstanding | 170.78M | 160.72M | 151.51M | 145.80M | 139.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |